31084-55-6Relevant articles and documents
Precise Labeling and Tracking of Lipid Droplets in Adipocytes Using a Luminescent ZnSalen Complex
Tang, Juan,Zhang, Yanfei,Yin, Hao-Yan,Xu, Guoheng,Zhang, Jun-Long
, p. 2533 - 2538 (2017)
Designing two-photon probes for precise labeling of lipid droplets (LDs) and monitoring LD dynamics in adipocytes is of great significance to understand LD homeostasis. We herein report that a luminescent metal complex LD-TPZn can specifically image LDs in adipose cells and tissue using one- or two-photon fluorescence microscopy. Importantly, LD-TPZn exhibited higher specificity to LDs than the commercial dyes Nile Red and Bodipy 493/503, probably due to different cellular uptake pathways, that is, clathrin-mediated endocytosis and non-selectively passive diffusion, respectively. More importantly, LD-TPZn can be applied as a two-photon LD probe to image adipose tissue, one of the most challengeable tissues for traditional one-photon fluorescence microscope imaging due to the strong light scattering. Most importantly, LD-TPZn can be used to monitor LD growth during adipogenesis of preadipocytes, which is highly desirable to unravel the relationship between LD homeostasis and metabolic diseases.
Copper(I)-catalyzed N-arylation of N1,N3- dibenzylmalonamide and N1,N3-dibutylmalonamide followed by cleavage of the malonyl group with aryl halides under ligand-free conditions
Zheng,Xu,Shi,Ren,Lu,Zhou
, p. 1117 - 1122 (2013/05/08)
We primarily developed a practical and convenient protocol to synthesize of aromatic amines based on CuI-catalyzed N-arylation of N1,N 3-dibenzylmalonamide and N1,N3- dibutylmalonamide followed by cleavage of the malonyl group with aryl halides under ligand-free conditions giving good yields.
SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS
-
Page/Page column 219, (2012/12/13)
Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.